Gene: FSD1L

83856
CCDC10|CSDUFD1|FSD1CL|FSD1NL|MIR1
fibronectin type III and SPRY domain containing 1 like
protein-coding
9q31.2
Ensembl:ENSG00000106701 MIM:609829 Vega:OTTHUMG00000020426 UniprotKB:Q9BXM9
NC_000009.12
SNP Mapped
1   ANCO-SNPs
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.148e-1 (AD)  8.368e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2149592chr9:105467709 (GRCh38.p7)A>Gnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SPAST0.895
RUFY30.876
KATNAL10.875
PPP1R9A0.868
ZBTB410.864
TMEFF10.864
TXNL10.864
KLHL20.86
TMEM1810.857
TRIM20.855

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.546
OR4F5-0.528
CSAG1-0.37
MTRNR2L8-0.345
MTRNR2L10-0.343
TTLL10-0.337
MTRNR2L2-0.332
RUNX3-0.331
KCNK5-0.316
C17orf82-0.315

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5116212-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Particulate Matter results in decreased expression of FSD1L mRNA]28655636
C5116212-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Vehicle Emissions results in decreased expression of FSD1L mRNA]28655636
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C006780bisphenol Abisphenol A results in decreased expression of FSD1L mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of FSD1L mRNA29097150
D000069286BortezomibBortezomib results in increased expression of FSD1L mRNA20977926
C030973cupric oxidecupric oxide results in increased expression of FSD1L mRNA22077320
D016572CyclosporineCyclosporine results in increased expression of FSD1L mRNA25562108
D002945CisplatinCisplatin results in decreased expression of FSD1L mRNA27392435
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of FSD1L mRNA29097150
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of FSD1L mRNA23649840
D005557FormaldehydeFormaldehyde results in decreased expression of FSD1L mRNA20655997
C045463leflunomideleflunomide results in increased expression of FSD1L mRNA28988120
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of FSD1L mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of FSD1L mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of FSD1L mRNA"26251327
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of FSD1L mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of FSD1L mRNA"25554681
D052638Particulate Matter2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Particulate Matter results in decreased expression of FSD1L mRNA]28655636
D052638Particulate MatterParticulate Matter results in decreased expression of FSD1L mRNA28655636
C086401pentabromodiphenyl etherpentabromodiphenyl ether analog results in increased expression of FSD1L mRNA19095052
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C006253pirinixic acidpirinixic acid results in increased expression of FSD1L mRNA20813756
C010327salinomycinsalinomycin results in decreased expression of FSD1L mRNA19682730
D013806TheophyllineTheophylline results in increased expression of FSD1L mRNA18951874
C483909torcetrapibtorcetrapib results in increased expression of FSD1L mRNA23228038
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of FSD1L mRNA26272509
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of FSD1L mRNA"26179874
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FSD1L mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of FSD1L mRNA23179753|2438349
D001335Vehicle Emissions2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Vehicle Emissions results in decreased expression of FSD1L mRNA]28655636
D001335Vehicle EmissionsVehicle Emissions results in decreased expression of FSD1L mRNA28655636
D014750VincristineVincristine results in increased expression of FSD1L mRNA23649840
C111237vorinostatvorinostat results in decreased expression of FSD1L mRNA27188386
C088658zoledronic acidzoledronic acid results in increased expression of FSD1L mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003674molecular_function-ND-  
GO ID GO Term Qualifier Evidence PubMed
GO:0008150biological_process-ND-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005575cellular_component-ND-  
GO:0005622intracellular-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal